Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 119

1.

Comment on "ALK is a therapeutic target for lethal sepsis".

Blasco RB, Patrucco E, Mota I, Tai WT, Chiarle R.

Sci Transl Med. 2018 Dec 12;10(471). pii: eaar4321. doi: 10.1126/scitranslmed.aar4321.

PMID:
30541790
2.

Wiskott-Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma.

Menotti M, Ambrogio C, Cheong TC, Pighi C, Mota I, Cassel SH, Compagno M, Wang Q, Dall'Olio R, Minero VG, Poggio T, Sharma GG, Patrucco E, Mastini C, Choudhari R, Pich A, Zamo A, Piva R, Giliani S, Mologni L, Collings CK, Kadoch C, Gambacorti-Passerini C, Notarangelo LD, Anton IM, Voena C, Chiarle R.

Nat Med. 2019 Jan;25(1):130-140. doi: 10.1038/s41591-018-0262-9. Epub 2018 Dec 3.

PMID:
30510251
3.

Parp3 promotes long-range end joining in murine cells.

Layer JV, Cleary JP, Brown AJ, Stevenson KE, Morrow SN, Van Scoyk A, Blasco RB, Karaca E, Meng FL, Frock RL, Tivey T, Kim S, Fuchs H, Chiarle R, Alt FW, Roberts SA, Weinstock DM, Day TA.

Proc Natl Acad Sci U S A. 2018 Oct 2;115(40):10076-10081. doi: 10.1073/pnas.1801591115. Epub 2018 Sep 13.

PMID:
30213852
4.

The CRISPR/Cas9 System as a Tool to Engineer Chromosomal Translocation In Vivo.

Cheong TC, Blasco RB, Chiarle R.

Adv Exp Med Biol. 2018;1044:39-48. doi: 10.1007/978-981-13-0593-1_4.

PMID:
29956290
5.

Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes.

Sharma GG, Mota I, Mologni L, Patrucco E, Gambacorti-Passerini C, Chiarle R.

Cancers (Basel). 2018 Feb 28;10(3). pii: E62. doi: 10.3390/cancers10030062. Review.

6.

KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS.

Ambrogio C, Köhler J, Zhou ZW, Wang H, Paranal R, Li J, Capelletti M, Caffarra C, Li S, Lv Q, Gondi S, Hunter JC, Lu J, Chiarle R, Santamaría D, Westover KD, Jänne PA.

Cell. 2018 Feb 8;172(4):857-868.e15. doi: 10.1016/j.cell.2017.12.020. Epub 2018 Jan 11.

7.

Epitope mapping of spontaneous autoantibodies to anaplastic lymphoma kinase (ALK) in non-small cell lung cancer.

Awad MM, Mastini C, Blasco RB, Mologni L, Voena C, Mussolin L, Mach SL, Adeni AE, Lydon CA, Sholl LM, Jänne PA, Chiarle R.

Oncotarget. 2017 Sep 23;8(54):92265-92274. doi: 10.18632/oncotarget.21182. eCollection 2017 Nov 3.

8.

Mitotic Spindle Assembly and Genomic Stability in Breast Cancer Require PI3K-C2α Scaffolding Function.

Gulluni F, Martini M, De Santis MC, Campa CC, Ghigo A, Margaria JP, Ciraolo E, Franco I, Ala U, Annaratone L, Disalvatore D, Bertalot G, Viale G, Noatynska A, Compagno M, Sigismund S, Montemurro F, Thelen M, Fan F, Meraldi P, Marchiò C, Pece S, Sapino A, Chiarle R, Di Fiore PP, Hirsch E.

Cancer Cell. 2017 Oct 9;32(4):444-459.e7. doi: 10.1016/j.ccell.2017.09.002.

9.

Combined immunodeficiency with EBV positive B cell lymphoma and epidermodysplasia verruciformis due to a novel homozygous mutation in RASGRP1.

Platt CD, Fried AJ, Hoyos-Bachiloglu R, Usmani GN, Schmidt B, Whangbo J, Chiarle R, Chou J, Geha RS.

Clin Immunol. 2017 Oct;183:142-144. doi: 10.1016/j.clim.2017.08.007. Epub 2017 Aug 16.

10.

A Braf kinase-inactive mutant induces lung adenocarcinoma.

Nieto P, Ambrogio C, Esteban-Burgos L, Gómez-López G, Blasco MT, Yao Z, Marais R, Rosen N, Chiarle R, Pisano DG, Barbacid M, Santamaría D.

Nature. 2017 Aug 10;548(7666):239-243. doi: 10.1038/nature23297. Epub 2017 Aug 2.

11.

Maternal Immunization: New Perspectives on Its Application Against Non-Infectious Related Diseases in Newborns.

Riccardo F, Réal A, Voena C, Chiarle R, Cavallo F, Barutello G.

Vaccines (Basel). 2017 Aug 1;5(3). pii: E20. doi: 10.3390/vaccines5030020. Review.

12.

Developmentally-faithful and effective human erythropoiesis in immunodeficient and Kit mutant mice.

Fiorini C, Abdulhay NJ, McFarland SK, Munschauer M, Ulirsch JC, Chiarle R, Sankaran VG.

Am J Hematol. 2017 Sep;92(9):E513-E519. doi: 10.1002/ajh.24805. Epub 2017 Jul 19.

13.

Primary Cutaneous B-Cell Lymphoblastic Lymphoma Arising from a Long-Standing Lesion in a Child and Review of the Literature.

Song H, Todd P, Chiarle R, Billett AL, Gellis S.

Pediatr Dermatol. 2017 Jul;34(4):e182-e186. doi: 10.1111/pde.13169. Epub 2017 May 26. Review.

PMID:
28547875
14.

Quantification of HER2 and estrogen receptor heterogeneity in breast cancer by single-molecule RNA fluorescence in situ hybridization.

Annaratone L, Simonetti M, Wernersson E, Marchiò C, Garnerone S, Scalzo MS, Bienko M, Chiarle R, Sapino A, Crosetto N.

Oncotarget. 2017 Mar 21;8(12):18680-18698. doi: 10.18632/oncotarget.15727.

15.

Phosphatidylinositol 3-kinase δ blockade increases genomic instability in B cells.

Compagno M, Wang Q, Pighi C, Cheong TC, Meng FL, Poggio T, Yeap LS, Karaca E, Blasco RB, Langellotto F, Ambrogio C, Voena C, Wiestner A, Kasar SN, Brown JR, Sun J, Wu CJ, Gostissa M, Alt FW, Chiarle R.

Nature. 2017 Feb 23;542(7642):489-493. doi: 10.1038/nature21406. Epub 2017 Feb 15.

16.

Comprehensive population-based genome sequencing provides insight into hematopoietic regulatory mechanisms.

Guo MH, Nandakumar SK, Ulirsch JC, Zekavat SM, Buenrostro JD, Natarajan P, Salem RM, Chiarle R, Mitt M, Kals M, Pärn K, Fischer K, Milani L, Mägi R, Palta P, Gabriel SB, Metspalu A, Lander ES, Kathiresan S, Hirschhorn JN, Esko T, Sankaran VG.

Proc Natl Acad Sci U S A. 2017 Jan 17;114(3):E327-E336. doi: 10.1073/pnas.1619052114. Epub 2016 Dec 28.

17.

Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia.

Griggio V, Mandili G, Vitale C, Capello M, Macor P, Serra S, Castella B, Peola S, Foglietta M, Drandi D, Omedé P, Sblattero D, Cappello P, Chiarle R, Deaglio S, Boccadoro M, Novelli F, Massaia M, Coscia M.

Oncotarget. 2017 Jan 10;8(2):3274-3288. doi: 10.18632/oncotarget.13712.

18.

Deep Sequencing Reveals a Novel miR-22 Regulatory Network with Therapeutic Potential in Rhabdomyosarcoma.

Bersani F, Lingua MF, Morena D, Foglizzo V, Miretti S, Lanzetti L, Carrà G, Morotti A, Ala U, Provero P, Chiarle R, Singer S, Ladanyi M, Tuschl T, Ponzetto C, Taulli R.

Cancer Res. 2016 Oct 15;76(20):6095-6106. Epub 2016 Aug 28.

19.

Oncogenic ALK regulates EMT in non-small cell lung carcinoma through repression of the epithelial splicing regulatory protein 1.

Voena C, Varesio LM, Zhang L, Menotti M, Poggio T, Panizza E, Wang Q, Minero VG, Fagoonee S, Compagno M, Altruda F, Monti S, Chiarle R.

Oncotarget. 2016 May 31;7(22):33316-30. doi: 10.18632/oncotarget.8955.

20.

Advances in cancer immunology and cancer immunotherapy.

Voena C, Chiarle R.

Discov Med. 2016 Feb;21(114):125-33. Review.

Supplemental Content

Loading ...
Support Center